{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 29,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide highlights both the clinical urgency (toxicity, resistance) and the commercial potential (orphan disease status).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/14",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "* Phase 3 trial dependent on securing partnership(s) or non-dilutive government funds",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faa294da-8fe5-484c-9311-5651ad4f5f4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.41
      },
      "kind": "list",
      "text": "IDSA Guidelines recommend treatment with mold-active azoles as first-line treatment for 6-12 weeks. Azole use requires significant expertise to manage toxicities and significant drug-drug interactions that often limits duration of use. Resistance to azoles has been increasing globally. Recently, cases of breakthrough IA have been reported in patients receiving antifungal prophylaxis. Failures attributed to non-compliance, poor absorption, DDIs, or infection with a drug-resistant Aspergillus species.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "574004db-77b7-4795-b871-9f7220e58d9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.69
      },
      "kind": "list",
      "text": "Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only). Rare disease/orphan commercial opportunity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5832e3ff-c8fc-4b00-bcf9-3ad2669c5248",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "list",
      "text": "Invasive aspergillosis (IA) is a serious and life-threatening invasive fungal infection that occurs primarily in severely immunocompromised patients with hematological malignancies and transplant recipients. ~15,000 new cases per year in the U.S. alone. WHO, CDC, and FDA consider IA a critical priority and a global public health concern.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d61bfa8-8865-4c01-9fca-57293b9bcde8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b79d315-8382-4b56-b58e-8add2bd87ac5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "d360ce26-d6da-4014-8ba5-78329052b0f3",
      "evidence": "High Unmet Medical Need in Treatment of Invasive Aspergillosis (IA)",
      "confidence": 0.8
    },
    {
      "name": "Storytelling: primary demands",
      "slug": "primary-demands",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "81c672b8-b0c7-475a-9f62-f79f50958c11",
      "evidence": "Patients suffering from IA with little or no treatment options among the highest unmet medical need with approximately 3,000-5,000 cases per year (U.S. only).",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "7aa25a8a-9932-4625-b5d8-1d7641445816",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem (Identify pain)",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the growing threat of IFIs and high unmet medical need in IA",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 14,
      "from": 14,
      "beatId": "4c746dd8-1e95-4d84-97e7-5921f00a9ef1",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document highlights the limitations of current treatments",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    },
    {
      "to": 17,
      "from": 8,
      "beatId": "eafaf135-71d7-4ccf-a416-5600c022e3da",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents MAT2203 as a solution and provides supporting evidence",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "280995d8-784d-4cf6-887d-11df1485e9b8",
      "evidence": "The document emphasizes the growing threat of IFIs",
      "position": 0,
      "objective": "Highlight the consequences of not addressing IFIs",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}